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ABSTRACT 
Warfarin has been the mainstay of preventing and treating thromboembolism for 
over 50 years and is currently taken by over 200,000 Australians.  Optimal 
management of warfarin relies on regular monitoring of the International 
Normalised Ratio (INR), appropriate dose adjustment, effective communication and 
comprehensive patient education.  Therapy may be managed by a range of 
healthcare providers in a variety of settings, and by patients themselves, although 
management in Australia has tended to focus on traditional office and pathology-
based models.  Internationally, however, alternative models of care are playing an 
increasingly significant role with positive results and pharmacists have been shown 
to be effective in improving the quality use of warfarin through a variety of these 
service delivery models. 
The main objective of this thesis was to examine the effect of using pharmacist-
delivered models of care on warfarin management within Australia through a 
number of complementary projects.   
Guidelines recommend aiming for a target INR control of upwards of 70% time in 
range.  Internationally, community-based studies consistently demonstrate 
suboptimal levels of INR control, although little data is available on the level of 
control achieved through usual models of care in Australia. A retrospective cross-
sectional study of INR results from 442 Australian veterans was undertaken to 
determine the INR control of a usual care population.  The mean time in INR range 
was 61.8% in this population.  This suggests a potential role for strategies aiming to 
improve INR control among Australian patients in line with best practice guidelines. 
Review of the literature suggested pharmacists could play a role in improving 
warfarin management through optimising the delivery of education, improving 
access to INR testing and facilitating patient self-monitoring. A series of sub-projects 
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were designed to develop and pilot tools to support pharmacists in addressing these 
strategies.  
A website was designed to provide patients and health professionals with 
educational resources regarding anticoagulation.  The site aimed to be a 
comprehensive and reliable online resource and was promoted directly to 
pharmacists.  It received high levels of utilisation, with almost 250,000 views in 12 
months, and positive feedback from health professionals and patients, and proved to 
be an important educational resource that was an easy and accessible tool for 
pharmacists to use to complement face to face counselling services and further 
improve patients’ knowledge about warfarin therapy. 
Tools and resources were developed to improve access to INR testing by facilitating 
the introduction of anticoagulation services, including pharmacist-delivered INR 
clinics, in Australia.  A pilot was conducted in three rural community pharmacies, 
with a subsequent project involving 36 pharmacies.  While the resources received 
positive feedback from participating pharmacists, the rate of successful service 
implementation was low.  Despite the perceived benefits to the communities, the 
current model of healthcare remuneration in Australia impacted on the long term 
financial viability of such services. 
Development, implementation and evaluation of a pharmacy-centred pathway to 
enable patient self-monitoring (PSM) was also undertaken.  Forty-eight patients 
successfully underwent training and participated in PSM for a median of 16.9 
months.  INR control data during PSM was compared to that from the six months 
prior to entering the study for 46 of the 48 patients.  There was a significant 
improvement in INR control, with the mean time in range increasing from 64.0% to 
72.9% (p<0.05).  Clinical data analysis was complemented by a qualitative 
exploration of 38 patients’ experiences of self-monitoring and the impact of PSM on 
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various aspects of their lives.  It was found that patients discussed PSM positively, 
describing it passionately and as something of value, which reduced their anxiety 
and freed them to carry on with their lives.   
The results of these projects suggest that expansion of the professional services 
offered by pharmacists has the potential to improve the control of warfarin therapy 
in Australia. Changes in remuneration for healthcare services are likely to increase 
the viability of pharmacist-delivered INR services and the uptake of PSM.  Despite 
the arrival of newer oral anticoagulant agents, the use of warfarin is likely to 
continue for many years.  Optimising warfarin management is arguably the safest 
and most clinically and cost-effective option for preventing and treating 
thromboembolism at this point in time.  Pharmacists can play an important role in 
improving warfarin management by embracing opportunities to deliver professional 
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